JPMorgan Chase & Co. Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

JPMorgan Chase & Co. lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 51.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 268,050 shares of the specialty pharmaceutical company’s stock after selling 286,785 shares during the period. JPMorgan Chase & Co.’s holdings in ANI Pharmaceuticals were worth $14,818,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. US Bancorp DE grew its position in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the period. KBC Group NV lifted its stake in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals during the fourth quarter valued at $166,000. HighTower Advisors LLC purchased a new stake in ANI Pharmaceuticals in the third quarter worth $222,000. Finally, China Universal Asset Management Co. Ltd. increased its position in ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 412 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $68.12 on Friday. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.00. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.48 billion, a P/E ratio of -123.85 and a beta of 0.49. The company has a 50 day moving average of $62.34 and a 200 day moving average of $59.07.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ANIP shares. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Finally, StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $79.75.

Insider Activity

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 in the last three months. Corporate insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.